首页> 美国卫生研究院文献>The Journal of Experimental Medicine >Diacylated Sulfoglycolipids Are Novel Mycobacterial Antigens Stimulating CD1-restricted T Cells during Infection with Mycobacterium tuberculosis
【2h】

Diacylated Sulfoglycolipids Are Novel Mycobacterial Antigens Stimulating CD1-restricted T Cells during Infection with Mycobacterium tuberculosis

机译:二酰化的磺基糖脂是结核分枝杆菌感染过程中刺激CD1限制T细胞的新型分枝杆菌抗原。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Mycobacterial lipids comprise a heterogeneous group of molecules capable of inducing T cell responses in humans. To identify novel antigenic lipids and increase our understanding of lipid-mediated immune responses, we established a panel of T cell clones with different lipid specificities. Using this approach we characterized a novel lipid antigen belonging to the group of diacylated sulfoglycolipids purified from Mycobacterium tuberculosis. The structure of this sulfoglycolipid was identified as 2-palmitoyl or 2-stearoyl-3-hydroxyphthioceranoyl-2′-sulfate-α-α′-d-trehalose (Ac2SGL). Its immunogenicity is dependent on the presence of the sulfate group and of the two fatty acids. Ac2SGL is mainly presented by CD1b molecules after internalization in a cellular compartment with low pH. Ac2SGL-specific T cells release interferon γ, efficiently recognize M. tuberculosis–infected cells, and kill intracellular bacteria. The presence of Ac2SGL-responsive T cells in vivo is strictly dependent on previous contact with M. tuberculosis, but independent from the development of clinically overt disease. These properties identify Ac2SGL as a promising candidate to be tested in novel vaccines against tuberculosis.
机译:分枝杆菌脂质包含能够在人体内诱导T细胞反应的异质性分子组。为了鉴定新的抗原脂质并增加我们对脂质介导的免疫反应的了解,我们建立了一组具有不同脂质特异性的T细胞克隆。使用这种方法,我们表征了一种新的脂质抗原,该抗原属于从结核分枝杆菌纯化的二酰化磺基糖脂类。该磺基糖脂的结构被鉴定为2-棕榈酰基或2-硬脂酰基-3-羟基苯硫基ceranoyl-2′-硫酸盐-α-α′-d-海藻糖(Ac2SGL)。它的免疫原性取决于硫酸盐基团和两种脂肪酸的存在。 Ac2SGL主要由CD1b分子内在低pH的细胞室内化后呈现。 Ac2SGL特异性T细胞释放γ干扰素,有效识别结核分枝杆菌感染的细胞,并杀死细胞内细菌。体内Ac2SGL反应性T细胞的存在严格取决于先前与结核分枝杆菌的接触,但与临床上明显疾病的发展无关。这些特性将Ac2SGL鉴定为有望在新型结核病疫苗中测试的候选药物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号